At CD BioSciences, our Molecular Diagnostics and Cancer Genetic Testing solutions provide integrated, high-precision genomic profiling services to propel oncology drug discovery, biomarker strategy, and clinical development. Combining state-of-the-art Next-Generation Sequencing (NGS) with quantitative PCR (qPCR), Digital PCR (dPCR), and Sanger Sequencing, we deliver comprehensive insights into tumor biology across both tissue and liquid biopsy samples.

Our regulatory-compliant testing infrastructure supports the full spectrum of genomic alteration analysis—including SNVs, InDels, Gene Fusions/Rearrangements, Copy Number Variations (CNVs), Microsatellite Instability (MSI), and Tumor Mutational Burden (TMB). Whether you require single-gene assays, custom pan-cancer Panels, or ultra-sensitive circulating tumor DNA (ctDNA) Minimal Residual Disease (MRD) monitoring, our team ensures audit-ready data.